NCT01235949 - Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and Prophylactic Antipyretic Treatment | Biotech Hunter

Enrollment

850

Participants

Timeline

Start Date

November 12, 2010

Primary Completion Date

March 28, 2012

Study Completion Date

December 8, 2012

Conditions

Infections, Streptococcal

Interventions

BIOLOGICAL

GSK1024850A (SynflorixTM)

Intramuscular injection, 4 doses

BIOLOGICAL

Infanrix hexa

Intramuscular injection, 3 doses

BIOLOGICAL

Infanrix-IPV/Hib

Intramuscular injection, 1 dose

DRUG

Ibuprofen

Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight

DRUG

Paracetamol

Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight

Trial Locations (23)

77145

GSK Investigational Site, Pantelimon

300593

GSK Investigational Site, Timișoara

400217

GSK Investigational Site, Cluj-Napoca

500063

GSK Investigational Site, Brasov

500260

GSK Investigational Site, Brasov

500366

GSK Investigational Site, Brasov

550166

GSK Investigational Site, Sibiu

600316

GSK Investigational Site, Bacau